Clinical trials: sponsored by AbbVie
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Non Small Cell Lung Cancer
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT05513703
- Testing
- Telisotuzumab Vedotin
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 9 people
- Sponsor
- AbbVie
Schizophrenia
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self.
- Trial name
- 509 JPN Schz (NCT05368558)
- Testing
- Cariprazine
- Where
- 52 sites in Japan, Taiwan
- Volunteers
- 34 people
- Sponsor
- AbbVie
Ulcerative Colitis
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
- Trial name
- NCT02632175
- Testing
- Adalimumab
- Where
- 16 sites in United States, Japan and 4 more
- Volunteers
- 59 people
- Sponsor
- AbbVie
Alzheimer's Disease (AD)
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- Abroad (NCT05771428)
- Testing
- ABBV-552
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 263 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie
Schizophrenia
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in…
- Trial name
- NCT05227690
- Testing
- Emraclidine 10 mg, Emraclidine 30 mg
- Where
- 25 sites in United States, Bulgaria
- Volunteers
- 385 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with…
- Trial name
- SELECT - PsA 2 (NCT03104374)
- Testing
- Upadacitinib
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 642 people
- Sponsor
- AbbVie
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MIRASOL (NCT04209855)
- Testing
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan
- Where
- 214 sites in United States, Australia and 19 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to…
- Trial name
- SELECT-COMPARE (NCT02629159)
- Testing
- Adalimumab, Upadacitinib
- Where
- 370 sites in United States, Argentina and 42 more
- Volunteers
- 1,629 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Flex-Up (NCT05507580)
- Testing
- Upadacitinib
- Where
- 106 sites in Australia, Belgium and 16 more
- Volunteers
- 461 people
- Sponsor
- AbbVie
Parkinson Disease
Fixed-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
- Trial name
- TEMPO-1 (NCT04201093)
- Testing
- Tavapadon
- Where
- 77 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- AbbVie
Chronic Migraine, Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
- Trial name
- JPN ATO OLE (NCT04437433)
- Testing
- Atogepant 60 mg
- Where
- 24 sites in Japan
- Volunteers
- 186 people
- Sponsor
- AbbVie
Heavy Menstrual Bleeding, Uterine Fibroids
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
This randomized multicenter phase 3b study seeks to evaluate the safety of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in…
- Trial name
- NCT03271489
- Testing
- Elagolix, Estradiol /norethindrone acetate (E2/NETA)
- Where
- 157 sites in United States, Puerto Rico
- Volunteers
- 478 people
- Sponsor
- AbbVie
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Dry Eye Disease, Dry Eye Syndrome
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
This was a 2-stage study in which Stage 1 evaluated the safety of AGN-242428 and AGN-231868, how well they are tolerated, and how they move through the body when administered.
- Trial name
- NCT04030962
- Testing
- AGN-242428, AGN-231868, AGN-242428 Vehicle
- Where
- 11 sites in United States
- Volunteers
- 292 people
- Sponsor
- AbbVie
Psoriasis
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-1 (NCT04435600)
- Testing
- Risankizumab, Ustekinumab
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Masseter Muscle Prominence
BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT04073303
- Testing
- Botulinum Toxin Type A
- Where
- 21 sites in Canada, China and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie
Hepatitis C Virus (HCV)
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
HCV infection is a global health problem. HCV mainly affects liver cells and causes the liver to become inflamed and damaged. This study will evaluate how safe and effective glecaprevir/pibrentasvir (GLE/PIB) is in adult and…
- Trial name
- NCT04903626
- Testing
- Glecaprevir/Pibrentasvir (GLE/PIB)
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 286 people
- Sponsor
- AbbVie